静脈血栓塞栓症治療の世界市場予測（～2030年）：製品別、病状別、エンドユーザー別、地域別の分析

世界の静脈血栓塞栓症治療の市場規模は、2023年に12億8,874万米ドルを占め、予測期間中にCAGR10.7％で成長し、2030年に26億2,543万米ドルに達すると予想されています。 新たな血栓の形成を防ぎ、合併症のリスクを下げ、血栓の溶解を促すために、静脈血栓塞栓症（VTE）治療は通常、多面的な戦略を伴います。

抗凝固薬は、肺塞栓症のような生命を脅かす結果を引き起こす可能性があるため、血栓の進展や塞栓を阻止するための即時管理で頻繁に使用されます。血栓の治療法は様々で、経口抗凝固薬からヘパリンのような静脈注射薬まで、血栓の部位や重症度によって異なります。

米国心臓協会によると、静脈血栓塞栓症（VTE）は公衆衛生にとって重大なリスクであり、米国だけでも年間60万件の発症が推定されています。

VTEに対する認識を高める

静脈血栓塞栓症（VTE）は、医学教育、意識向上キャンペーン、および患者支援プログラムへの取り組みが強化された結果、重大なヘルスケア上の懸念事項として広く認識されるようになりました。VTEの危険因子、症状、および適切な診断技術の特定は、ヘルスケア専門家のトレーニングの重要な部分となりつつあります。さらに、患者がVTEに関する知識を深めるにつれて、早期に介入し、できるだけ早く医師の診察を受けることがいかに重要であるかを理解するようになっています。さらに、啓発キャンペーンを後押しし、VTEが臨床診療や公衆衛生の課題における最重要事項であり続けることを保証するのが、医学会や団体によるガイドラインや勧告の配布です。

法外な治療費

抗凝固薬、診断検査、入院、治療後のケアなど、VTEの治療に関連する費用は、患者、保険者、ヘルスケアシステムに大きな経済的負担を強います。新規経口抗凝固薬（NOAC）は、ワルファリンよりもモニタリングの必要性が少ないにもかかわらず、しばしば高価であるため、特に資源が限られている環境では、その利用可能性が制限されます。さらに、高リスクの血栓性疾患やVTEの再発など、特定の患者集団では抗凝固療法を長期間継続する必要があるため、治療費はさらに増大します。

直接経口抗凝固薬（DOAC）の使用の増加

直接トロンビン阻害薬と第Xa因子阻害薬は、市場で急成長を遂げている直接経口抗凝固薬（DOACs）の2つの例です。迅速な作用発現、予測可能な薬物動態、薬物相互作用リスクの低減は、DOACが従来の抗凝固療法と比較して有する利点のほんの一部に過ぎません。急性VTEの治療、血栓予防の延長、二次性VTEの予防におけるDOACの安全性と有効性がより多くの臨床データによって証明されるにつれて、DOACの使用は増加すると予想されます。さらに、現在進行中の研究では、投与レジメンの改良、新規適応の検討、出血性合併症に対処するための逆転薬の開発などにより、VTE治療におけるDOACの有効性をさらに向上させることを目指しています。

薬剤耐性の増加

VTE治療における抗凝固療法の有効性は、薬剤耐性の出現によって深刻な脅威にさらされています。薬物代謝に影響を及ぼす遺伝的変異、薬物標的の後天的変異、治療レジメンの不遵守などは、抗凝固薬に対する耐性をもたらす要因の一部です。耐性の発現は抗凝固薬の治療効果を低下させる可能性があり、その結果、治療が失敗し、血栓イベントのリスクが高くなります。さらに、VTEを適切に治療することの困難さは、抗凝固薬耐性を獲得した患者に対する代替治療の選択肢が乏しいことによって、さらに深刻なものとなっています。

COVID-19の影響

静脈血栓塞栓症（VTE）治療市場力学は、COVID-19の流行によって影響を受けています。重篤なCOVID-19症例における血栓性合併症に対する意識の高まりにより抗凝固療法に対する需要が増加しているにもかかわらず、医療提供体制、選択的処置、患者ケア経路の変化により、VTE診断および治療開始の遅れが生じています。VTE治療薬の処方パターンや市場力学は、リソースの制約、サプライチェーンの混乱、ヘルスケアの優先事項の変化によっても影響を受けています。さらに、製薬会社やVTE治療のプロバイダーは、患者の保険適用範囲の縮小やヘルスケア予算の制約など、パンデミックの経済的影響によるさらなる課題に直面しています。

予測期間中、抗凝固薬セグメントが最大となる見込み

静脈血栓塞栓症（VTE）を抗凝固薬で治療するセグメントが最大の市場シェアを占めています。血栓の形成、塞栓、血栓イベントの再発を予防するため、抗凝固薬はVTEの管理に不可欠です。抗凝固薬にはさまざまな剤形があるため、患者はそれぞれの特性や臨床的ニーズに応じて治療法を選択することができます。さらに、抗凝固薬には非経口薬と経口薬があります。VTEを急性的に治療し、抗凝固療法によって長期的に血栓塞栓性合併症を予防することが推奨されています。

予測期間中にCAGRが最も高くなると予想されるのは外来医療センターセグメント

静脈血栓塞栓症（VTE）治療市場に関しては、通常、外来医療センターセグメントが最も高いCAGRを示します。VTEを含むさまざまな病状の診断、治療、管理のための外来サービスは、外来医療センターによって提供されます。さらに、外来診療への傾斜が強まっている背景には、医療費の上昇、低侵襲手術の開発、患者の利便性と費用対効果を優先するバリューベースのケアモデルの採用など、さまざまな要因が考えられます。

最大のシェアを持つ地域：

北米が最も大きなシェアを占めているのは、確立されたヘルスケアシステム、高い医療費、高度な診断ツール、肥満や座りがちな生活習慣、高齢化といったVTEリスク因子の高い有病率といった要因によるものです。北米の市場拡大をさらに後押ししているのは、有力な業界企業の存在、継続的な研究開発イニシアティブ、有利な償還慣行です。さらに、VTEの予防、診断、治療に対する積極的な取り組みや、患者およびヘルスケア専門家の意識の高まりもあり、この地域はVTE治療市場で世界をリードしています。

CAGRが最も高い地域：

欧州は静脈血栓塞栓症（VTE）治療市場において最も高いCAGRを示す地域です。高齢化、肥満、座りっぱなしのライフスタイルなど、一般的になりつつある危険因子を含む多くの要因が、この成長とVTE症例の発生率増加の原因となっています。さらに、治療方法、診断方法、ヘルスケアインフラの改善により、VTEを制御する能力が向上しています。さらに、強力な研究開発努力、ヘルスケア改革、支援的な規制枠組みが技術革新を促進し、市場拡大を後押ししています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の静脈血栓塞栓症治療市場：製品別

• 血栓除去装置
• 下大静脈フィルター
  • 回収可能フィルター
  • 永久フィルター
• ストッキング
• 抗凝固薬
• 圧縮ポンプ
• その他の製品

第6章 世界の静脈血栓塞栓症治療市場：病状別

• 深部静脈血栓症
• 肺塞栓症
• その他の病状

第7章 世界の静脈血栓塞栓症治療市場：エンドユーザー別

• 病院と診療所
• 外来診療センター
• カテーテル検査室
• その他のエンドユーザー

第8章 世界の静脈血栓塞栓症治療市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東・アフリカ

第9章 主な発展

• 協定、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Mitsubishi Tanabe Pharma Corporation
• Cardinal Health, Inc.
• Koninklijke Philips N.V.
• Boston Scientific Corporation
• Johnson & Johnson
• Stryker Corporation
• Sanofi
• Abbott Laboratories
• Leo Pharma A/S
• Novartis AG
• Pfizer Inc.
• Mylan N.V.
• Argon Medical Devices, Inc.
• Medtronic plc
• Teva Pharmaceutical Industries Ltd.
• LifeTech Scientific Corporation
• Bayer AG
• CSL Limited
• Biogenics Inc.

List of Tables

• Table 1 Global Venous Thromboembolism Treatment Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
• Table 4 Global Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
• Table 5 Global Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
• Table 6 Global Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
• Table 7 Global Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
• Table 8 Global Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
• Table 9 Global Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
• Table 10 Global Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 11 Global Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 12 Global Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
• Table 13 Global Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
• Table 14 Global Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 15 Global Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 16 Global Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
• Table 17 Global Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 18 Global Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 19 Global Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 20 North America Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 21 North America Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 22 North America Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
• Table 23 North America Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
• Table 24 North America Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
• Table 25 North America Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
• Table 26 North America Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
• Table 27 North America Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
• Table 28 North America Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
• Table 29 North America Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 30 North America Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 31 North America Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
• Table 32 North America Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
• Table 33 North America Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 34 North America Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 35 North America Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
• Table 36 North America Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 37 North America Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 38 North America Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 39 Europe Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 40 Europe Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 41 Europe Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
• Table 42 Europe Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
• Table 43 Europe Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
• Table 44 Europe Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
• Table 45 Europe Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
• Table 46 Europe Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
• Table 47 Europe Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
• Table 48 Europe Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 49 Europe Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 50 Europe Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
• Table 51 Europe Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
• Table 52 Europe Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 53 Europe Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 54 Europe Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
• Table 55 Europe Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 56 Europe Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 57 Europe Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 58 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 59 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 60 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
• Table 61 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
• Table 62 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
• Table 63 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
• Table 64 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
• Table 65 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
• Table 66 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
• Table 67 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 68 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 69 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
• Table 70 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
• Table 71 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 72 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 73 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
• Table 74 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 75 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 76 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 77 South America Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 78 South America Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 79 South America Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
• Table 80 South America Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
• Table 81 South America Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
• Table 82 South America Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
• Table 83 South America Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
• Table 84 South America Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
• Table 85 South America Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
• Table 86 South America Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 87 South America Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 88 South America Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
• Table 89 South America Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
• Table 90 South America Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 91 South America Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 92 South America Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
• Table 93 South America Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 94 South America Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 95 South America Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 96 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 97 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 98 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
• Table 99 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
• Table 100 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
• Table 101 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
• Table 102 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
• Table 103 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
• Table 104 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
• Table 105 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 106 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 107 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
• Table 108 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
• Table 109 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 110 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 111 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
• Table 112 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 113 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
• Table 114 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Venous Thromboembolism Treatment Market is accounted for $1288.74 million in 2023 and is expected to reach $2625.43 million by 2030 growing at a CAGR of 10.7% during the forecast period. In order to prevent new clot formation, lower the risk of complications, and encourage clot dissolution, venous thromboembolism (VTE) treatment usually entails a multifaceted strategy. Anticoagulant drugs, which can cause life-threatening outcomes like pulmonary embolism, are frequently used in immediate management to stop clot extension and embolization. Treatments for blood clots can vary, ranging from oral anticoagulants to intravenous drugs like heparin, depending on their location and severity.

According to the American Heart Association, venous thromboembolism (VTE) poses a significant risk to public health, with an estimated incidence of up to 600,000 cases per year in the United States alone.

Market Dynamics:

Driver:

Raising awareness of VTE

Venous thromboembolism (VTE) is now more widely acknowledged as a serious healthcare concern as a result of increased efforts in medical education, awareness campaigns, and patient advocacy programs. The identification of VTE risk factors, symptoms, and suitable diagnostic techniques is becoming a more important part of healthcare professionals training. Additionally, as patients gain more knowledge about VTE, they realize how critical it is to intervene early and seek medical attention as soon as possible. Further boosting awareness campaigns and guaranteeing that VTE stays a top concern in clinical practice and public health agendas is the distribution of guidelines and recommendations by medical societies and organizations.

Restraint:

Exorbitant treatment expenses

The expenses associated with treating VTE, such as anticoagulant drugs, diagnostic exams, hospital stays, and post-treatment care, can place a heavy financial strain on patients, insurers, and healthcare systems. Despite having fewer monitoring requirements than warfarin, novel oral anticoagulants (NOACs) are frequently more expensive, which limits their accessibility, particularly in settings with limited resources. Furthermore, treatment costs are further increased by the requirement for extended-duration anticoagulation therapy in specific patient populations, such as those with high-risk thrombophilic conditions or recurrent VTE.

Opportunity:

Increasing use of direct oral anticoagulants (DOACs)

Direct thrombin inhibitors and factor Xa inhibitors are two examples of direct oral anticoagulants (DOACs) that are seeing rapid growth in the market. The rapid onset of action, predictable pharmacokinetics, and reduced risk of drug interactions are just a few benefits that DOACs have over conventional anticoagulant therapies. It is anticipated that the use of DOACs will rise as more clinical data demonstrates their safety and effectiveness in treating acute VTE, prolonging thromboprophylaxis, and preventing secondary VTE. Additionally, ongoing studies aim to further improve the effectiveness of DOACs in the treatment of VTE by refining dosage regimens, investigating novel indications, and creating reversal medications to address bleeding complications.

Threat:

Rise in medication resistance

The efficacy of anticoagulant therapies in the treatment of VTE is seriously threatened by the emergence of drug resistance. Genetic variations affecting drug metabolism, acquired mutations in drug targets, and non-adherence to treatment regimens are some of the factors that can lead to resistance to anticoagulants. Resistance development could reduce anticoagulant drugs therapeutic effectiveness, which would result in treatment failure and a higher risk of thrombotic events. Moreover, the difficulty of adequately treating VTE is further compounded by the scarcity of alternative treatment options for patients who have developed anticoagulant resistance.

Covid-19 Impact:

Venous thromboembolism (VTE) treatment market dynamics have been affected by the COVID-19 pandemic. Delays in VTE diagnosis and treatment initiation have been caused by changes in healthcare delivery, elective procedures, and patient care pathways, even as the demand for anticoagulant therapies has increased due to the increased awareness of thrombotic complications in severe COVID-19 cases. The prescribing patterns and market dynamics for VTE treatments have also been impacted by resource limitations, disruptions in the supply chain, and changes in healthcare priorities. Additionally, pharmaceutical companies and providers of VTE treatment face additional challenges due to the economic effects of the pandemic, such as reduced patient insurance coverage and healthcare budget constraints.

The Anticoagulant Medications segment is expected to be the largest during the forecast period

The segment that treats venous thromboembolism (VTE) with anticoagulant medications holds the largest market share. In order to prevent clot formation, embolization, and recurrent thrombotic events, anticoagulants are essential to the management of VTE. Patients can choose their treatment according to their individual characteristics and clinical needs because these medications come in a variety of formulations. Furthermore, these include parenteral agents and oral anticoagulants. It is advised to treat VTE acutely and prevent thromboembolic complications over the long term with anticoagulant therapy.

The Ambulatory Care Centers segment is expected to have the highest CAGR during the forecast period

When it comes to the Venous Thromboembolism (VTE) Treatment Market, the ambulatory care center segment usually has the highest CAGR. Outpatient services for the diagnosis, treatment, and management of a range of medical conditions, including VTE, are provided by ambulatory care centers. Moreover, the growing inclination towards ambulatory care can be attributed to various factors, including rising healthcare costs, developments in minimally invasive procedures, and the adoption of value-based care models that prioritize patient convenience and cost effectiveness.

Region with largest share:

North America usually has the largest share, due to factors, like well-established healthcare system, high healthcare costs, sophisticated diagnostic tools, and a high prevalence of VTE risk factors like obesity, sedentary lifestyles, and aging populations, are responsible for this dominance. Further supporting the market expansion in North America is the existence of significant industry players, continuous R&D initiatives, and advantageous reimbursement practices. Additionally, due in part to the region's proactive approach to VTE prevention, diagnosis, and treatment, as well as rising patient and healthcare professional awareness, it leads the world in the VTE treatment market.

Region with highest CAGR:

Europe is the region that frequently exhibits the highest CAGR in the market for treatments for venous thromboembolism (VTE). A number of factors, including the aging population, obesity, and sedentary lifestyles, which are risk factors that are becoming more common, are responsible for this growth and the increased incidence of VTE cases. Furthermore, improvements in treatment modalities, diagnostic methods, and healthcare infrastructure improve the area's ability to control VTE. In addition, robust R&D efforts, healthcare reforms, and supportive regulatory frameworks encourage innovation and propel market expansion.

Key players in the market

Some of the key players in Venous Thromboembolism Treatment market include Mitsubishi Tanabe Pharma Corporation, Cardinal Health, Inc., Koninklijke Philips N.V., Boston Scientific Corporation, Johnson & Johnson, Stryker Corporation, Sanofi, Abbott Laboratories, Leo Pharma A/S, Novartis AG, Pfizer Inc., Mylan N.V., Argon Medical Devices, Inc., Medtronic plc, Teva Pharmaceutical Industries Ltd., LifeTech Scientific Corporation, Bayer AG, CSL Limited and Biogenics Inc.

Key Developments:

In January 2024, Cardinal Health Inc. announced an agreement to buy Specialty Networks for $1.2 billion in cash, as the drug distributor and medical products maker looks to enhance its data analytics capabilities. The company said the acquisition expands its offering in therapeutic areas and increases its data and research opportunities with biopharmaceutical manufacturers.

In January 2024, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price is $71 in cash per share, reflecting an equity value of approximately $3.7 billion and an enterprise value of approximately $3.4 billion.

In January 2024, Johnson & Johnson has reached tentative agreement to resolve talc baby powder claims with more than 40 states, the world's biggest maker of health care products confirmed. That progress includes an agreement in principle that the company reached with a consortium of 43 State Attorneys Generals to resolve their talc claims.

Products Covered:

• Thrombectomy Devices
• Inferior Vena Cava Filters
• Stockings
• Anticoagulant Medications
• Compression Pumps
• Other Products

Disease Indications Covered:

• Deep Vein Thrombosis
• Pulmonary Embolism
• Other Disease Indications

End Users Covered:

• Hospitals and Clinics
• Ambulatory Care Centers
• Catheterization Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Venous Thromboembolism Treatment Market, By Product

• 5.1 Introduction
• 5.2 Thrombectomy Devices
• 5.3 Inferior Vena Cava Filters
  • 5.3.1 Retrievable Filters
  • 5.3.2 Permanent Filters
• 5.4 Stockings
• 5.5 Anticoagulant Medications
• 5.6 Compression Pumps
• 5.7 Other Products

6 Global Venous Thromboembolism Treatment Market, By Disease Indication

• 6.1 Introduction
• 6.2 Deep Vein Thrombosis
• 6.3 Pulmonary Embolism
• 6.4 Other Disease Indications

7 Global Venous Thromboembolism Treatment Market, By End User

• 7.1 Introduction
• 7.2 Hospitals and Clinics
• 7.3 Ambulatory Care Centers
• 7.4 Catheterization Laboratories
• 7.5 Other End Users

8 Global Venous Thromboembolism Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Mitsubishi Tanabe Pharma Corporation
• 10.2 Cardinal Health, Inc.
• 10.3 Koninklijke Philips N.V.
• 10.4 Boston Scientific Corporation
• 10.5 Johnson & Johnson
• 10.6 Stryker Corporation
• 10.7 Sanofi
• 10.8 Abbott Laboratories
• 10.9 Leo Pharma A/S
• 10.10 Novartis AG
• 10.11 Pfizer Inc.
• 10.12 Mylan N.V.
• 10.13 Argon Medical Devices, Inc.
• 10.14 Medtronic plc
• 10.15 Teva Pharmaceutical Industries Ltd.
• 10.16 LifeTech Scientific Corporation
• 10.17 Bayer AG
• 10.18 CSL Limited
• 10.19 Biogenics Inc.